Raptor Pharmaceutical Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-12-21: Form 8-K; Period of report 2011-12-15; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2011-10-26: Form 8-K; Period of report 2011-10-25; Description 8.01 Other Events; Details 8.01.
- 2011-09-28: Form 8-K; Period of report 2011-09-22; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2011-09-19: Form 8-K; Period of report 2011-09-13; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-12-21 | 8-K | 2011-12-15 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On December 19, 2011, the Company issued a press release that details the execution of the Agreement and the purposes of the Agreement. | raptor8k122011.htm |
| 2011-10-26 | 8-K | 2011-10-25 | 8.01 Other Events | 8.01 On October 25, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that the Company concluded a pre-New Drug Application meeting with the U.S. Food and Drug Administration related to its investigational drug candidate, RP103 (delayed-release formulation of cysteamine bitartrate), for the treatment of nephropathic cystinosis. | raptor8k102611.htm |
| 2011-09-28 | 8-K | 2011-09-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 22, 2011, the Board of Directors (the “Board”) of Raptor Pharmaceutical Corp. (the “Company”) approved an amended and restated form of Award Agreement (the “New Award Agreement”) under the Company’s 2010 Stock Incentive Plan, as amended from time to time (the “Plan”). | raptor8k092811.htm |
| 2011-09-19 | 8-K | 2011-09-13 | 8.01 Other Events | 8.01 On September 13, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing the closing of its previously announced underwritten public offering of shares of its common stock at a price to the public of $4.00 per share. | raptor8k091911.htm |
| 2011-09-08 | 8-K | 2011-09-08 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 7, 2011, the Company issued a news release announcing the commencement of the offering. | raptor8kfinancing090811.htm |
| 2011-07-26 | 8-K | 2011-07-25 | 8.01 Other Events | 8.01 On July 25, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that it will host a conference call and webcast at noon, Eastern Time, on July 26, 2011, to comment on the Company’s Phase 3 RP103 positive clinical trial results. | raptor8kcc072511.htm |
| 2011-07-25 | 8-K | 2011-07-25 | 8.01 Other Events | 8.01 On July 25, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that its Phase 3 clinical trial of Delayed Release or DR Cysteamine, known as study drug RP103, for the treatment of nephropathic cystinosis, met the primary endpoint of non-inferiority compared to Cystagon®, immediate-release cysteamine bitartrate. | raptor8k072511.htm |
| 2011-06-28 | 8-K | 2011-06-22 | 8.01 Other Events | 8.01 Through June 22, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company) has issued 155,029 shares of the Company’s common stock pursuant to the exercise of Series A Warrants for $379,821 in gross proceeds to the Company and 1,873,779 shares of the Company’s common stock pursuant to the exercise of the Series B Warrants for $4,590,759 in gross proceeds to the Company; such Series A and Series B Warrants were issued in connection with the Company’s registered direct offering completed in December 2009. | raptor8k062711.htm |
| 2011-04-13 | 8-K | 2011-04-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On April 11, 2011, the board of directors (the “Board”) of Raptor Pharmaceutical Corp. (the “Company”) appointed Suzanne L. Bruhn, Ph.D., Vijay B. Samant and Timothy P. Walbert to the Board. 8.01 A copy of the press release announcing the appointment of Dr. Bruhn, Mr. Samant and Mr. Walbert to the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. | raptor8k041311.htm |
| 2011-04-07 | 8-K | 2011-04-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Raptor Pharmaceutical Corp.’s 2011 Annual Meeting of Stockholders (the “Annual Meeting”) was held on April 7, 2011. | form8k040711.htm |
| 2011-03-22 | 8-K | 2011-03-22 | 8.01 Other Events | 8.01 On March 22, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), announced that its 2011 annual meeting of stockholders scheduled for March 22, 2011, was adjourned due to the lack of a requisite quorum. | form8k032211.htm |
| 2011-02-15 | 8-K | 2011-02-15 | 8.01 Other Events | 8.01 On February 15, 2011, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis. | form8k021511.htm |